Consumer Electronics, PCs & Audio Hardware Brands · vs · Pharmaceuticals, Biotech & Life Sciences Brands
ASSA ABLOY vs Johnson & Johnson
Structured technology and market comparison · 2026
Direct Feature Comparison
ASSA ABLOY · vs · Johnson & Johnson| Attribute | ||
|---|---|---|
| Market Cluster / Sector | Consumer Electronics, PCs & Audio Hardware Brands | Pharmaceuticals, Biotech & Life Sciences Brands |
| Business Model / Role | Advertiser / Brand | Advertiser / Brand |
| Platform Focus | Global access solutions and physical security products manufacturer. | Large public healthcare manufacturer and commercial products company. |
| Company Size | >5,000 employees | >5,000 employees |
| Headquarters | Sweden | United States |
| Year Founded | 1994 | 1887 |
| Dossier & Alternatives |
Analyze all overlapping signals and tech stacks for ASSA ABLOY and Johnson & Johnson
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between ASSA ABLOY and Johnson & Johnson?
When comparing ASSA ABLOY and Johnson & Johnson, both platforms operate within the Advertiser / Brand ecosystem. ASSA ABLOY is positioned as Global access solutions and physical security products manufacturer, whereas Johnson & Johnson focuses on Large public healthcare manufacturer and commercial products company. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to ASSA ABLOY and Johnson & Johnson?
When evaluating ASSA ABLOY and Johnson & Johnson, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of ASSA ABLOY and Johnson & Johnson compare?
ASSA ABLOY is headquartered in Sweden (founded in 1994) with >5,000 employees. Johnson & Johnson is based in United States (founded in 1887) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: ASSA ABLOY vs Johnson & Johnson
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
ASSA ABLOY
Recent Signals
- ·PR Newswire: Technology NewsM&A
ASSA ABLOY divests PKI business to Vista Equity Partners
ASSA ABLOY has signed an agreement to sell its PKI business unit, part of HID, to Vista Equity Partners. The unit provides digital trust, identity, authentication, encryption, and certificate management solutions, including PKI SaaS platforms IdenTrust, HydrantID, and ZeroSSL. In 2025, the divested business generated sales of approximately USD 58 million (SEK 570 million) with a strong operating margin. The transaction is subject to customary closing conditions and is expected to close in Q4 2026. The sale reflects ASSA ABLOY's strategic portfolio management, while Vista Equity Partners, a private equity firm, will take over the business to support its growth.
- ASSA ABLOY signed an agreement to sell its PKI business unit to Vista Equity Partners.
- The PKI business unit includes IdenTrust, HydrantID, and ZeroSSL products.
- The divested business had sales of USD 58 million (approx. SEK 570 million) in 2025.
Johnson & Johnson
Recent Signals
- ·SEC APIfinancials
Johnson & Johnson Furnishes Q3 2026 Earnings Announcement via Current Report
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
- Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
- Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
- Total present value of reserves for talc-related legal matters reached approximately $9.0 billion as of September 27, 2026, while the planned separation of the Orthopaedics business remains on track for mid-2027.
- ·Johnson & JohnsonProduct & Platform Launch
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
- ·Johnson & JohnsonProduct & Platform Launch
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Johnson & Johnson published a behind-the-scenes feature on September 25, 2026, highlighting how the company manufactures and delivers CAR-T cell therapy for multiple myeloma. The article focuses on the complexity of producing and distributing this personalized cancer treatment. No specific clinical data, product names, or commercial terms are disclosed in the provided text.
- Johnson & Johnson published a behind-the-scenes feature on September 25, 2026.
- The article focuses on Johnson & Johnson's CAR-T cell therapy manufacturing and delivery for multiple myeloma.
- The provided article text does not reveal specific product names, trial results, or financial terms.
Start with a company or market. Track what changes.
Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.
ASSA ABLOY vs. Johnson & Johnson
Compare capabilities, ecosystem relationships, and recent signals side by side in Polaris7.
Company Comparisons
Compare capabilities, ecosystem relationships, and recent signals side by side in Polaris7.
